.tb-field[data-toolset-blocks-field="9c806f05a2136c4ac06e5a74e85a9bb3"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="3fecc53c2177c9d5c742c172297af8a2"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="a6f55e954f267703e48f4b60e541ee8a"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

Filter by Company

News and Press Releases

Healthcare Finance and Smart Materials Experts Delivering Opening and Closing Plenaries at PharmSci 360

26 June 2025 -- Virginia, US -- AAPS is excited to announce the opening and closing plenary speakers for the 2025 PharmSci 360, taking place November 9-12, in San Antonio,...

Category: Biotechnology, Drug Delivery, Logistics, Other, Pharmaceutical
Posted: June 26, 2025

American Association of Pharmaceutical Scientists (AAPS)

aaps@aaps.org

2107 Wilson Blvd #200 Arlington, VA 22201

Oxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for Bunyaviricetes

France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance BUNYANTIVIR project to introduce novel therapeutic approach for Bunyaviricetes class of human pathogenic viruses found in tropical and...

Category:
Posted: June 25, 2025

Oxeltis

Cap Gamma, 1682 rue de la Valsière, BP 7247 34086 Montpellier Cedex 4 – France

Novo Nordisk A/S: Ozempic receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities

Pending a decision from the European Commission, Ozempic (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, demonstrating improvements in blood sugar,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 23, 2025

Novo Nordisk

abmo@novonordisk.com

Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2025

argenx

ukmediainfo@argenx.com

Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG

Neopac Wins Two Prestigious Tube of the Year Awards from the US Tube Council

Oberdiessbach, Switzerland – Neopac, a global provider of high-quality packaging and dosing applications for pharma, beauty and oral care, has received two prestigious Tube of the Year Awards from the...

Category:
Posted: June 20, 2025

Neopac

info@neopac.com

3672 Oberdiessbach

New Reverse Osmosis (RO) pure water dialysis system unveiled by NIPRO at ERA 2025

19 June 2025 -- Osaka, Japan -- NIPRO announces the launch of LiniXia, a strategic addition to its dialysis portfolio in next-generation reverse-osmosis (RO) water treatment. The new LiniXia RO...

Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: June 19, 2025

Nipro Medical Corporation

info@nipromed.com

Sanner starts manufacturing in Greensboro, USA

18 June 2025 -- North Carolina, US -- Sanner has officially launched manufacturing operations in Greensboro, North Carolina. The new facility is dedicated to producing critical injection-molded components for medical...

Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical, Pharmaceutical Contractors
Posted: June 18, 2025

Sanner

info@sanner-group.com

Schillerstrasse 76 64625 Bensheim

Celltrion opens new UK headquarters in Uxbridge, UK

New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK 17 June 2025 -- London, UK -- Celltrion UK has officially opened its new...

Category: Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 17, 2025

Celltrion

23, Academy-ro, Yeonsu-gu, Incheon, Republic of Korea

SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers

Recognises the potential of Aurase Wound Gel to improve outcomes for individuals with calciphylaxis ulcers, a rare and life-threatening condition Represents a new indication for Aurase Wound Gel, currently in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 16, 2025

SolasCure

wellington house East Rd, Petersfield, Cambridge CB1 1BH

Kite’s CAR T-Cell Therapy Data Show Real-World Patient Benefit and Durable Response Across Difficult-to-Treat Blood Cancers

Largest Real-World (RW) Analyses of Yescarta® (Axicabtagene Ciloleucel) Show 74% Overall Survival (OS) at 12 Months in Second-Line Relapsed/Refractory Large B-cell Lymphoma (LBCL), Consistent with OS Reported in Pivotal ZUMA-7 Study,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: June 12, 2025

Kite Pharma

2400 Broadway Santa Monica, CA 90404

Lightning-Fast Gut Microbiome Analysis Opens New Doors for Health and Industry

12 June 2025 -- Leuven, Belgium -- A revolution in gut microbiome research is on the horizon. Biotech company Perseus Biomics and hardware developer Comate are launching MetaMAP, a groundbreaking...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: June 12, 2025

Perseus Biomics

info@perseusbiomics.com

Gaston Geenslaan 3 3001 Leuven, Belgium

Northern Gritstone invests in Manchester spinout Apini

Northern Gritstone has committed £1.8 million to Apini, a spinout from the University of Manchester Apini is a novel small molecule therapeutic programme for the treatment of multiple chronic inflammatory...

Category: Biotechnology, Other, Pharmaceutical
Posted: June 11, 2025

Northern Gritstone

enquiries@northern-gritstone.com

No.1 Circle Square 3 Symphony Park Manchester M1 7FS

Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections

Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections Novel bifunctional molecule based on Alphamer platform demonstrated direct, broad-spectrum antibacterial activity in vitro...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 10, 2025

Centauri

info@centauritherapeutics.com

Discovery Park, Sandwich CT13 9ND

PEPperPRINT GmbH Launches cLIFT Technology for Next-Generation Peptide Microarrays

10 June 2025 -- Heidelberg, Germany -- PEPperPRINT, a global leader in peptide microarray technology, celebrates its 15th anniversary with the launch of its next-generation peptide microarray platform: cLIFT, short for...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 10, 2025

PEPperPRINT

info@pepperprint.com

Tullastrasse 2 D-69126 Heidelberg Germany

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. 10 June...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 10, 2025